Merck invested $610mil in Absci. Merck's blockbuster ($20.9bil in 2022) drug Keytruda is being mouse trialed at M.D. Anderson alongside Leronlimab. Keytruda's patent is approaching its expiration date (2028) and needs help to continue busting blocks. Dots to connect.